Search Results - "LEYLAND-JONES"

Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Central Nervous System Metastases by Brian Leyland-Jones

“…To determine the incidence, outcomes, and current strategies for management of brain metastases in patients with human epidermal growth factor receptor 2…”
Get full text

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials by Dey, Nandini, De, Pradip, Leyland-Jones, Brian

“…Breast cancer (BC) is the most common women cancer and second most common cause of cancer death in women. A woman living in the United States has 12.3%…”
Get full text

Breast cancer trial with erythropoietin terminated unexpectedly by Leyland-Jones, Brian

Get more information

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial by Cameron, David, Prof, Piccart-Gebhart, Martine J, PhD, Gelber, Richard D, PhD, Procter, Marion, PhD, Goldhirsch, Aron, MD, de Azambuja, Evandro, MD, Castro, Gilberto, MD, Untch, Michael, MD, Smith, Ian, MD, Gianni, Luca, MD, Baselga, Jose, MD, Al-Sakaff, Nedal, PhD, Lauer, Sabine, PhD, McFadden, Eleanor, MA, Leyland-Jones, Brian, MBBS, Bell, Richard, MBBS, Dowsett, Mitch, PhD, Jackisch, Christian, MD

“…Summary Background Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall…”
Get full text

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study by Sicklick, Jason K., Kato, Shumei, Okamura, Ryosuke, Schwaederle, Maria, Hahn, Michael E., Williams, Casey B., De, Pradip, Krie, Amy, Piccioni, David E., Miller, Vincent A., Ross, Jeffrey S., Benson, Adam, Webster, Jennifer, Stephens, Philip J., Lee, J. Jack, Fanta, Paul T., Lippman, Scott M., Leyland-Jones, Brian, Kurzrock, Razelle

“…Cancer treatments have evolved from indiscriminate cytotoxic agents to selective genome- and immune-targeted drugs that have transformed the outcomes of some…”
Get full text

Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500 by Smerage, Jeffrey B, Barlow, William E, Hortobagyi, Gabriel N, Winer, Eric P, Leyland-Jones, Brian, Srkalovic, Gordan, Tejwani, Sheela, Schott, Anne F, O'Rourke, Mark A, Lew, Danika L, Doyle, Gerald V, Gralow, Julie R, Livingston, Robert B, Hayes, Daniel F

“…Increased circulating tumor cells (CTCs; five or more CTCs per 7.5 mL of whole blood) are associated with poor prognosis in metastatic breast cancer (MBC). A…”
Get full text

Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors by Dey, Nandini, De, Pradip, Brian, Leyland-Jones

“…Vascular endothelial growth factor (VEGF) dependent tumor angiogenesis is an essential step for the initiation and promotion of tumor progression. The…”
Get full text

Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer by Aapro, M, Jelkmann, W, Constantinescu, S N, Leyland-Jones, B

“…Erythropoiesis-stimulating agents (ESAs) increase red blood cell (RBC) production in bone marrow by activating the erythropoietin receptor (EpoR) on…”
Get full text

Mutation Matters in Precision Medicine: A Future to Believe In by Nandini, Dey, Casey, Williams, Brian, Leyland-Jones, Pradip, De

“…Graphical abstract…”
Get full text

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti‐HER2 targeted therapies by Ross, Jeffrey S., Gay, Laurie M., Wang, Kai, Ali, Siraj M., Chumsri, Saranya, Elvin, Julia A., Bose, Ron, Vergilio, Jo‐Anne, Suh, James, Yelensky, Roman, Lipson, Doron, Chmielecki, Juliann, Waintraub, Stanley, Leyland‐Jones, Brian, Miller, Vincent A., Stephens, Philip J.

“…BACKGROUND Activating, nonamplification ERBB2 mutations (ERBB2mut) are not detected by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH),…”
Get full text

Doubling Down on the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness by De, Pradip, Sun, Yuling, Carlson, Jennifer H, Friedman, Lori S, Leyland-Jones, Brian R, Dey, Nandini

“…Abstract Phosphoinositide 3-kinase (PI3K) pathway, in addition to its pro-proliferative and antiapoptotic effects on tumor cells, contributes to DNA damage…”
Get full text

Wnt signaling in triple negative breast cancer is associated with metastasis by Dey, Nandini, Barwick, Benjamin G, Moreno, Carlos S, Ordanic-Kodani, Maja, Chen, Zhengjia, Oprea-Ilies, Gabriella, Tang, Weining, Catzavelos, Charles, Kerstann, Kimberly F, Sledge, Jr, George W, Abramovitz, Mark, Bouzyk, Mark, De, Pradip, Leyland-Jones, Brian R

“…Triple Negative subset of (TN) Breast Cancers (BC), a close associate of the basal-like subtype (with limited discordance) is an aggressive form of the disease…”
Get full text

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial by Goldhirsch, Aron, Prof, Gelber, Richard D, Prof, Piccart-Gebhart, Martine J, Prof, de Azambuja, Evandro, MD, Procter, Marion, MSci, Suter, Thomas M, Prof, Jackisch, Christian, Prof, Cameron, David, Prof, Weber, Harald A, MD, Heinzmann, Dominik, PhD, Lago, Lissandra Dal, MD, McFadden, Eleanor, MA, Dowsett, Mitch, Prof, Untch, Michael, Prof, Gianni, Luca, MD, Bell, Richard, Prof, Köhne, Claus-Henning, Prof, Vindevoghel, Anita, MD, Andersson, Michael, MD, Brunt, A Murray, MD, Otero-Reyes, Douglas, MD, Song, Santai, MD, Smith, Ian, Prof, Leyland-Jones, Brian, PhD, Baselga, Jose, Prof

“…Summary Background Trastuzumab has established efficacy against breast cancer with overexpression or amplification of the HER2 oncogene. The standard of care…”
Get full text

Erythropoiesis stimulating agents: a personal journey by Leyland-Jones, Brian

“…Leylan-Jones talks about a personal journey of a medical oncologist who is desperately trying to improve the outcomes of women suffering from breast cancer. At…”
Get full text

Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study by LEYLAND-JONES, Brian, SEMIGLAZOV, Vladimir, BIAKHOV, Mikhail, VALUCKAS, Konstantinas, VOZNYI, Edouard, XIANGYANG LIU, VERCAMMEN, Els, PAWLICKI, Marek, PIENKOWSKI, Tadeusz, TJULANDIN, Sergei, MANIKHAS, George, MAKHSON, Antoly, ROTH, Anton, DODWELL, David, BASELGA, Jose

“…To evaluate the effect on survival and quality of life of maintaining hemoglobin (Hb) in the range of 12 to 14 g/dL with epoetin alfa versus placebo in women…”
Get full text

Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis by Willis, Scooter, Villalobos, Victor M, Gevaert, Olivier, Abramovitz, Mark, Williams, Casey, Sikic, Branimir I, Leyland-Jones, Brian

“…To discover novel prognostic biomarkers in ovarian serous carcinomas. A meta-analysis of all single genes probes in the TCGA and HAS ovarian cohorts was…”
Get full text

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01) by DE AZAMBUJA, Evandro, PROCTER, Marion J, JACKISCH, Christian, CAMERON, David A, BELL, Richard, LEYLAND-JONES, Brian, DOWSETT, Mitch, GELBER, Richard D, PICCART-GEBHART, Martine J, SUTER, Thomas M, VAN VELDHUISEN, Dirk J, AGBOR-TARH, Dominique, METZGER, Otto, STEINSEIFER, Jutta, UNTCH, Michael, SMITH, Ian E, GIANNI, Luca, BASELGA, Jose

“…To document the rate and outcome of trastuzumab-associated cardiac dysfunction in patients following 1 or 2 years of adjuvant therapy. The Herceptin Adjuvant…”
Get full text

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel by LEYLAND-JONES, Brian, GELMON, Karen, AYOUB, Jean-Pierre, ARNOLD, Andrew, VERMA, Shail, DIAS, Reg, GHAHRAMANI, Parviz

“…This phase II study evaluated the pharmacokinetics and safety of trastuzumab and paclitaxel given every 3 weeks to women with human epidermal growth factor…”
Get full text

RET rearrangements are actionable alterations in breast cancer by Paratala, Bhavna S., Chung, Jon H., Williams, Casey B., Yilmazel, Bahar, Petrosky, Whitney, Williams, Kirstin, Schrock, Alexa B., Gay, Laurie M., Lee, Ellen, Dolfi, Sonia C., Pham, Kien, Lin, Stephanie, Yao, Ming, Kulkarni, Atul, DiClemente, Frances, Liu, Chen, Rodriguez-Rodriguez, Lorna, Ganesan, Shridar, Ross, Jeffrey S., Ali, Siraj M., Leyland-Jones, Brian, Hirshfield, Kim M.

“…Fusions involving the oncogenic gene RET have been observed in thyroid and lung cancers. Here we report RET gene alterations, including amplification, missense…”
Get full text

Proteomics: New technologies and clinical applications by Latterich, Martin, Abramovitz, Mark, Leyland-Jones, Brian

“…Abstract During the past decade, various genomics-based techniques have been applied with increasing success to the molecular characterisation of breast…”
Get full text